Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers.
about
New and emerging treatments for epilepsy: review of clinical studies of lacosamide, eslicarbazepine acetate, ezogabine, rufinamide, perampanel, and electrical stimulation therapyPharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human.Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study.Ezogabine: a new angle on potassium gates.Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizuresNeuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.Clinical utility of adjunctive retigabine in partial onset seizures in adults.Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.Ezogabine (KCNQ2/3 channel opener) prevents delayed activation of meningeal nociceptors if given before but not after the occurrence of cortical spreading depression.Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults.Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.Novel medications for epilepsy.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Retigabine for partial onset seizures.Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine.Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditionsThe anticonvulsant retigabine is a subtype selective modulator of GABAA receptors.Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians.Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects.The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine.
P2860
Q27007942-9791A430-A890-49F3-BA7F-FD766E9EC190Q34137634-51E73514-3B77-4D34-96E1-D89DCFDDE7DAQ34333196-1509F26F-12C3-4E31-B300-AB81B5541A6DQ34386899-AB015FD7-E1E8-4A4A-8E0E-E822875053BDQ35052160-2F7C47D7-9254-4C2C-9E59-A2B2D804AD5DQ35117817-6C7DEF74-01B0-4D46-B728-F130204F63A9Q35683922-7D7F5CEE-F4BF-489F-9B83-F05EB01B9276Q35717049-4288001B-84A7-45B9-A76D-4EAE2D5D5D15Q36144410-181783AE-72CD-4242-8574-599072BBB76FQ36980156-B31B6B49-82EB-4378-BEC9-66C043BF242AQ37302567-98109725-A54A-4446-8CA8-043A79EC150EQ37589301-DF576140-E504-4EBA-B415-EA1D3F4F745EQ37754477-6058BC56-166E-4D87-BA32-E1129DCCA005Q37831297-A7664B74-E5A5-4BEF-BDB9-2B2693710052Q37936428-42B49546-C5F9-4181-AEBD-E2D65DD3C55EQ37950518-214AC75C-F512-4B96-AD6F-56A0E0AEE11BQ37992162-A95A64A0-1124-40E6-91DD-82E64830C031Q38006978-ECE97B42-54AF-4E15-9CF3-B2272E459BF8Q38044694-3789FE8C-CEE9-4D51-8867-44F165C46C87Q38079563-BF75EBBF-4AE2-4040-84EB-EFE751242989Q38621010-E9FBA8D2-6F1D-4061-9E8D-4218D9B49762Q38851234-C15D7F16-B240-43A9-981A-D4F691C9D4B4Q40615041-A9400214-BB45-4D9F-8276-EC134E4D5044Q41771260-33888060-4F05-44C2-B371-390FB4FBBC4AQ42212418-1BD225AE-9AE8-4D50-8457-9694D3C5AB03Q42385228-BB4F05C9-46D6-4316-9FDC-839472C1D1DEQ42760045-8429F773-BEBE-4A11-B5F5-CE660C23B3A8Q44405609-12E705A4-678F-4B48-AA70-3E88381C53BAQ46886423-990B5FCD-48C6-4278-A201-0CEED8F2F4A6
P2860
Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@ast
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@en
type
label
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@ast
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@en
prefLabel
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@ast
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@en
P2093
P2860
P1476
Multiple-dose, linear, dose-pr ...... igabine in healthy volunteers.
@en
P2093
Geraldine M Ferron
Jeffrey Paul
John Getsy
Lyette Richards
Norbert Knebel
Richard Fruncillo
Steven Troy
P2860
P304
P356
10.1177/00912700222011210
P577
2002-02-01T00:00:00Z